Premium
BDNF levels are not related with levodopa‐induced dyskinesias in MPTP monkeys
Author(s) -
Samadi Pershia,
Morissette Marc,
Lévesque Daniel,
Di Paolo Thérèse
Publication year - 2010
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.22885
Subject(s) - mptp , levodopa , dyskinesia , neuroscience , parkinson's disease , medicine , psychology , degenerative disease , pharmacology , central nervous system disease , disease
Levodopa‐induced dyskinesias (LIDs) are frequent in parkinsonian patients and may result from an aberrant plasticity. Brain‐derived neurotrophic factor (BDNF) represents a likely candidate to subserve neuroadaptive processes encountered in LIDs. We compared striatal BDNF levels measured by ELISA in levodopa‐treated 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) monkeys having developed LIDs compared with animals where LIDs were prevented by the addition of CI‐1041 (NR1A/2B NMDA receptor antagonist) or low doses of cabergoline (dopamine D2 receptor agonist). We observed reduced striatal BDNF concentrations in levodopa‐treated MPTP monkeys with or without LIDs, suggesting that levodopa treatment is associated with reduced striatal BDNF levels and is independent of dyskinesias. © 2009 Movement Disorder Society